Iovance Biotherapeutics Reports 62.5% ORR and No-Reached Median OS in Final Phase 2 Analysis of Lifileucel Plus Pembrolizumab for Frontline Advanced Melanoma

Iovance Biotherapeutics reported phase 2 data showing a 62.5% objective response rate and 29.2% complete response rate for Amtagvi combined with Merck's Keytruda in first-line melanoma patients. The data was presented at a medical conference.

Iovance reported Phase 2 data showing 62.5% ORR and 29.2% CR for lifileucel plus pembrolizumab in frontline advanced melanoma. Median OS not reached at 50.9 months' follow-up. The results support a potential shift to frontline use, aligning with Phase 3 strategy.

Iovance Biotherapeutics (IOVA) announced that its lifileucel combined with pembrolizumab showed promising results in a Phase 2 trial for frontline advanced melanoma. The study reported a median progression-free survival of 19.8 months, with median overall survival not reached at over 4 years. The company is conducting a Phase 3 trial (TILVANCE-301) to support potential approval for this combination therapy. Iovance estimates a global market of 70,000 patients annually for this indication.

A phase II trial of 42 patients with follicular lymphoma (FL) or marginal zone lymphoma (MZL) showed a 100% overall response rate and 86% complete response rate to mosunetuzumab, a CD20×CD3 bispecific antibody. The study used a response-adapted approach, adding polatuzumab vedotin and obinutuzumab for partial responders. Two-year progression-free survival was 89%. The trial suggests potential for chemo-free frontline therapy, though long-term data are needed.

The Trump administration is considering easing sanctions on select shadow-fleet vessels, potentially increasing competition for tanker operators like DHT Holdings (DHT), Frontline (FRO), and International Seaways (INSW). Shares of these companies and a tanker-freight ETF declined last week. DHT reported strong Q3 earnings, while International Seaways announced a $370M acquisition. Analysts question if sanctions relief would significantly lower tanker rates.

Iovance Biotherapeutics [IOVA] reported Q2 2026 revenue of $99.3m, raising full-year guidance to $410m-$420m. Its FDA-approved TIL therapy, Amtagvi, faces logistical challenges but shows commercial momentum. IOVA stock surged 28% post-guidance upgrade, up 433% YTD. Competitors include Immunocore [IMCR] and Bristol-Myers Squibb [BMY].